Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

JAK inhibitor

- PMLiVE

Pfizer’s RSV vaccine candidate accepted for FDA priority review for use in older adults

A phase 3 study showed the vaccine was 85.7% effective in those with three or more symptoms

- PMLiVE

Enzyvant and Altavant announce merger to accelerate rare disease therapies

The combined company is in the process of developing in-house manufacturing

- PMLiVE

Pfizer and Clear Creek Bio partner on COVID-19 antiviral research programme

The companies will identify a papain-like protease candidate to progress into the clinic

- PMLiVE

ORIGINS cements its specialist position with a truly patient focused offering

Origins are the patient focused specialists that create and deliver strategy, insights, experience data and solutions across the product lifecycle

Origins – The Patient Focused Specialists

- PMLiVE

Pfizer/BioNTech submit FDA application for BA.4/BA.5 COVID-19 vaccine in children under five

The vaccine is already authorised as a booster for ages five years and older in the US and EU

- PMLiVE

LEO Pharma’s delgocitinib cream shows promise in phase 3 chronic hand eczema study

There are no topical treatments specifically developed and approved for moderate-to-severe CHE

- PMLiVE

Pfizer and Roivant form new company to develop inflammatory disease drug

RVT-3101 is currently being evaluated in a global phase 2b study for ulcerative colitis

- PMLiVE

Pfizer and Valneva report six-month antibody persistence data for Lyme disease vaccine

VLA15 is the only Lyme disease vaccine candidate currently in clinical development

- PMLiVE

FREE WEBINAR: End-to-end patient strategy: making a treatment for patients, with patients

Origins announces the first speaker on the panel of our upcoming webinar

Origins – The Patient Focused Specialists

How to tell a better silent story

How To Tell A Better Silent Story

They say a picture's worth 1,000 words, which is incredibly helpful when telling a silent story.

The Good Ideas Group

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers

The PD-1 inhibitor demonstrated a statistically significant benefit in overall survival

- PMLiVE

Sanofi/Regeneron’s Dupixent receives CHMP recommendation for prurigo nodularis

Two phase 3 trials showed a reduction in itch, skin lesions and health-related quality of life

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links